Literature DB >> 25631529

Are patients with X-linked agammaglobulinemia at increased risk of developing acute lymphoblastic leukemia?

Mary Ellen Conley1.   

Abstract

Entities:  

Mesh：

Year:  2015        PMID： 25631529     DOI： 10.1007/s10875-015-0132-x

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN： 0271-9142            Impact factor:   8.317


× No keyword cloud information.
  16 in total

Review 1.  Bruton's tyrosine kinase inhibitors and their clinical potential in the treatment of B-cell malignancies: focus on ibrutinib.

Authors:  Amin Aalipour; Ranjana H Advani
Journal:  Ther Adv Hematol       Date:  2014-08

2.  Genotype/phenotype correlations in X-linked agammaglobulinemia.

Authors:  Arnon Broides; Wenjian Yang; Mary Ellen Conley
Journal:  Clin Immunol       Date:  2005-11-16       Impact factor: 3.969

3.  Agammaglobulinemia.

Authors:  O C BRUTON
Journal:  Pediatrics       Date:  1952-06       Impact factor: 7.124

Review 4.  Molecular approaches to analysis of X-linked immunodeficiencies.

Authors:  M E Conley
Journal:  Annu Rev Immunol       Date:  1992       Impact factor: 28.527

Review 5.  Gastric adenocarcinoma in the context of X-linked agammaglobulinemia: case report and review of the literature.

Authors:  Aidé Tamara Staines Boone; María Guadalupe Torres Martínez; Gabriela López Herrera; Julia O de Leija Portilla; Sara Elva Espinosa Padilla; Francisco J Espinosa Rosales; Saúl Oswaldo Lugo Reyes
Journal:  J Clin Immunol       Date:  2013-12-12       Impact factor: 8.317

6.  The adaptor protein SLP-65 acts as a tumor suppressor that limits pre-B cell expansion.

Authors:  Alexandra Flemming; Tilman Brummer; Michael Reth; Hassan Jumaa
Journal:  Nat Immunol       Date:  2002-11-18       Impact factor: 25.606

Review 7.  Acute lymphoblastic leukaemia.

Authors:  Hiroto Inaba; Mel Greaves; Charles G Mullighan
Journal:  Lancet       Date:  2013-03-22       Impact factor: 79.321

8.  Defective expression of Bruton's tyrosine kinase in acute lymphoblastic leukemia.

Authors:  Patricia A Goodman; Carla M Wood; Alexei O Vassilev; Chen Mao; Fatih M Uckun
Journal:  Leuk Lymphoma       Date:  2003-06

9.  Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia.

Authors:  S Tsukada; D C Saffran; D J Rawlings; O Parolini; R C Allen; I Klisak; R S Sparkes; H Kubagawa; T Mohandas; S Quan
Journal:  Cell       Date:  1993-01-29       Impact factor: 41.582

10.  Bruton's tyrosine kinase cooperates with the B cell linker protein SLP-65 as a tumor suppressor in Pre-B cells.

Authors:  Rogier Kersseboom; Sabine Middendorp; Gemma M Dingjan; Katarina Dahlenborg; Michael Reth; Hassan Jumaa; Rudolf W Hendriks
Journal:  J Exp Med       Date:  2003-06-30       Impact factor: 14.307
View more
  4 in total

Review 1.  The pre-B-cell receptor checkpoint in acute lymphoblastic leukaemia.

Authors:  J Eswaran; P Sinclair; O Heidenreich; J Irving; L J Russell; A Hall; D P Calado; C J Harrison; J Vormoor
Journal:  Leukemia       Date:  2015-05-06       Impact factor: 11.528

Review 2.  A Tumor Profile in Primary Immune Deficiencies Challenges the Cancer Immune Surveillance Concept.

Authors:  Daniel Satgé
Journal:  Front Immunol       Date:  2018-05-24       Impact factor: 7.561

3.  Functional Antibody Responses Following Allogeneic Stem Cell Transplantation for TP53 Mutant pre-B-ALL in a Patient With X-Linked Agammaglobulinemia.

Authors:  Menno C van Zelm; Marsus Pumar; Peter Shuttleworth; Pei M Aui; Joanne M Smart; Andrew Grigg; Julian J Bosco
Journal:  Front Immunol       Date:  2019-04-26       Impact factor: 7.561

Review 4.  Hallmarks of Cancers: Primary Antibody Deficiency Versus Other Inborn Errors of Immunity.

Authors:  Hassan Abolhassani; Yating Wang; Lennart Hammarström; Qiang Pan-Hammarström
Journal:  Front Immunol       Date:  2021-08-17       Impact factor: 7.561
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.